Pacific Biosciences of California (PACB) ended the recent trading session at $1.44, demonstrating a +1.41% change from the preceding day's closing price. The stock's change was more than the S&P 500's ...

PACB's strong Q4 results, expanding sequencing tech portfolio and rising system adoption highlight growth momentum despite ...

The latest analyst update for Pacific Biosciences of California cuts the rating to Underweight and trims the price target from US$2 to US$1.50, while keeping a fair value estimate of US$2.43 per share ...

In the latest close session, Pacific Biosciences of California (PACB) was down 6.67% at $1.26. The stock trailed the S&P 500, which registered a daily loss of 1.67%. At the same time, the Dow lost ...

Pacific Biosciences of California (NASDAQ:PACB) ranks among the best CRISPR stocks to buy. Speaking on its strategic developments and challenges, Pacific Biosciences of California (NASDAQ:PACB) ...

We recently published These 10 Stocks are Winning Big. Pacific Biosciences of California, Inc. (NASDAQ:PACB) is one of the best-performing stocks on Monday. Pacific Biosciences jumped by 6.49 percent ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Wintrust Financial (WTFC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

MENLO PARK, Calif. (AP) — MENLO PARK, Calif. (AP) — Pacific Biosciences of California Inc. (PACB) on Thursday reported a loss of $40.4 million in its fourth quarter. On a per-share basis, the Menlo ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, delivered an adjusted loss per share of 12 cents in third-quarter 2025, narrower than the year-ago adjusted loss of 17 cents ...